HSP 59.38 Hospira Inc $HSP Hit a 52 week high of 59.49

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
HSP 59.38 Hospira Inc $HSP Hit a 52 week high of 59.49 Closing the day 09:44 at 59.38 -0.34 -0.57% With a day low of 58.95 and a total volume of 44,115.

HSP Recent Posts: http://investorshangout.com/Hospira-Inc-HSP-51354/

HSP Hospira Inc Recent Headline News

Earnings Look Back: Hospira Is Up 2.9% Since Reporting Quarterly Results 1 Week Ago (HSP)
Comtex SmarTrend(R) - Mon Nov 17, 11:31AM CST
When Hospira (NYSE:HSP) reported earnings a week ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $0.54 on sales of $1.1 billion. Hospira actually reported earnings of $0.74 per share on sales of $1.2 billion, beating EPS estimates by $0.20 and beating revenue estimates by $68.6 million. Shares of Hospira have climbed from $56.64 to $58.28, representing a gain of 2.9% since the company reported earnings 11 days ago.
HSP: 58.97 (-0.75)

Hospira Mourns Passing of Founding Board Member Dr. Connie R. Curran
PR Newswire - Mon Nov 17, 9:30AM CST
The board of directors and employees of Hospira, Inc. (NYSE: HSP) today expressed their deepest sorrow over the loss of Connie R. Curran, R.N., Ed. D, one of the company's founding board members. Dr. Curran had served as a member of the Hospira Board since 2004, providing invaluable contributions to the business through her strategic leadership, exceptional command of the healthcare industry and shared passion for the company's commitment to putting patients first.
HSP: 58.97 (-0.75)

Hospira Has Returned 11.8% Since SmarTrend Recommendation (HSP)
Comtex SmarTrend(R) - Fri Nov 14, 10:02AM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on October 24th, 2014 at $51.84. In approximately 3 weeks, Hospira has returned 11.79% as of today's recent price of $57.95.
HSP: 58.97 (-0.75)

Earnings Triple Plays
Bespoke Investment Group - Seeking Alpha - Wed Nov 12, 1:54AM CST
The third quarter earnings season unofficially comes to an end on Thursday when Wal-Mart (NYSE: WMT ) reports earnings before the open. So far this earnings season, more than 2,000 companies have reported their quarterly numbers, and our job here is...
GD: 143.40 (-0.53), ACT: 267.93 (-1.67), CBG: 32.88 (-0.26), HCP: 43.59 (-0.45), BCR: 166.02 (-1.34), PCG: 50.18 (-0.24), AMGN: 162.18 (-0.06), CB: 101.75 (+0.01), SRE: 109.97 (-0.51), PLD: 40.98 (-0.40), HSP: 58.97 (-0.75), TWX: 80.97 (+0.47), KIM: 24.83 (-0.02), CMI: 143.37 (-1.47), ALXN: 193.02 (+0.65), ESS: 199.02 (-2.19), ABBV: 65.55 (-0.50), CAT: 101.55 (-0.49), AAPL: 114.25 (-1.22)

Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST

CANF: 3.68 (+0.68), JNJ: 108.26 (-0.57), IDRA: 2.54 (+0.06), DERM: 16.06 (-0.23), MRK: 59.49 (-0.40), PFE: 30.34 (-0.25), AZN: 74.77 (+0.79), AMGN: 162.18 (-0.06), GSK: 46.14 (-0.14), HSP: 58.97 (-0.75), NVS: 95.44 (-0.14), CELG: 106.89 (+0.11)

Hospira Inc.'s Third-Quarter Earnings: The 3 Key Takeaways
Leo Sun, The Motley Fool - Motley Fool - Fri Nov 07, 10:53AM CST
Shares of Hospira jumped nearly 7% on Nov. 6 after the maker of injectable drugs and infusion technologies reported impressive third-quarter earnings. Source: Wikimedia Commons. Hospira's revenue climbed 2% year over year to $1.2 billion,...
HSP: 58.97 (-0.75)

Stock Market News for November 07, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
Benchmarks ended in the green zone yesterday following ECB President Mario Draghi’s statement regarding possible expansion of monetary stimulus by the European Central Bank
DHI: 24.63 (unch), WFM: 47.85 (-0.04), TSLA: 247.36 (-10.34), LEN: 45.57 (-0.12), QCOM: 70.67 (-1.34), PHM: 21.00 (-0.30), TOL: 33.86 (-0.03), GNW: 9.21 (-0.15), HSP: 58.97 (-0.75)

Strength Seen in Hospira (HSP): Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:25AM CST
Hospira (HSP) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 83.90 (-1.66), ABAX: 54.20 (-0.41), GWPH: 80.33 (-0.17), HSP: 58.97 (-0.75)

Look for Shares of Hospira to Potentially Pullback after Yesterday's 6.67% Rise
Comtex SmarTrend(R) - Thu Nov 06, 4:13PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $55.00 to a high of $58.00. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $53.88 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HSP: 58.97 (-0.75)

Watch for Hospira to Potentially Pullback After Gaining 6.67% Yesterday
Comtex SmarTrend(R) - Thu Nov 06, 4:13PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $55.00 to a high of $58.00. Yesterday, the shares gained 6.7%, which took the trading range above the 3-day high of $53.88 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
HSP: 58.97 (-0.75)

Hospira Beats on Earnings & Sales in Q3, Narrows Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:53PM CST
Hospira reported third-quarter 2014 adjusted earnings of 74 cents per share.
AGN: 213.47 (+0.10), ABAX: 54.20 (-0.41), ABBV: 65.55 (-0.50), HSP: 58.97 (-0.75)

Hospira (HSP) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Thu Nov 06, 12:39PM CST
The following Hospira (HSP) conference call took place on November 6, 2014, 09:00 AM ET. This is a transcript of that earnings call:
HSP: 58.97 (-0.75)

Hospira's (HSP) CEO Michael Ball on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 12:20PM CST

HSP: 58.97 (-0.75)

Hospira Q3 income up big
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:11AM CST

HSP: 58.97 (-0.75)

Hospira (HSP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 7:55AM CST

HSP: 58.97 (-0.75)

Hospira unveils generic Paricalcitol Injection in three multi-dose sizes
M2 - Thu Nov 06, 7:28AM CST
Injectable drug company
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hi3D Unlocks AI 3D Model for Open-Source Innovation

Updated Category News Views 3

A New Era in 3D Model Accessibility Unless you’ve been hiding under a rock, it’s hard to miss how digital terraforming has shifted gears. With Hi3D V1.0 opening its doors, the playing field's getting a major reshuffle. Or, as they say, the table is being set, and everyone's getting a seat. By letting loose production-validated AI tools, Hi3D is throwing down the...

Continue Reading
Unicycive's Stock Plunge: Fraud Suit and FDA Hurdles

Updated Category News Views 7

Unicycive's Tumultuous Journey Lately, it's been a rocky road for Unicycive Therapeutics, Inc., with their stock free-falling 39.1% in the span of a heartbeat on June 30, 2026. What sparked this nosedive? The FDA kicked back their revised New Drug Application for a kidney disease treatment yet again, spotlighting old manufacturing issues never nipped in the bud. Talk...

Continue Reading
NYC's Carriage Horse Ban: A New Era for Urban Welfare

Updated Category News Views 4

You've got to hand it to New York City—this isn't just another Tuesday twist. The City Council's decision to nix horse-drawn carriages is like throwing a wrench in an antique machine. It's a bold move in a concrete jungle that's constantly wearing new coats. Tradition vs. Welfare: The Crux For years, the idea of horses prancing down NYC streets seemed like a quaint nod...

Continue Reading
Basic Invite's Holiday Card Service Offers Saving Time

Updated Category News Views 1

Getting the Cards Out: Maneuvering the Holiday Hustle Alright, let's dive into the madness that is holiday card season. Could be a logistical nightmare or a nostalgic tradition, depending on your cup of tea. Basic Invite here is trying to cut through the chaos by bumping deadlines and offering some straight-out-the-gate mailing options. If you play your cards right—pun...

Continue Reading
D-Wave Investors Face Pressure Ahead of December 15

Updated Category News Views 3

Investors Eye December 15 Deadline Nothing like a looming deadline to stir up some anxiety among investors, and that's exactly what's going down at D-Wave Quantum Inc. right now. We're talking about the class action lawsuit spearheaded by the firm Robbins Geller Rudman & Dowd LLP. They've sent out a call to arms for investors who suffered significant losses from February...

Continue Reading
Celebrating Alexander Trost: A Lifetime of Compassionate Care

Updated Category News Views 4

A Legendary Career in Palliative Medicine You know, in a world where people glamorize stock flips and flashy earnings, it's refreshing to spotlight good old-fashioned compassion. Enter Dr. Alexander Trost, DNP, FNP-C, ACHPN. This fella has just been honored as a Pinnacle Lifetime Member by The Inner Circle—a nod to his impactful work in palliative medicine. You ever try...

Continue Reading
Tigo Energy Faces Class Action Over Revenue Claims

Updated Category News Views 3

Trouble Brewing for Tigo Energy? Straight from the horse's mouth, we hear about Tigo Energy (NASDAQ: TYGO) getting embroiled in a class action smackdown. Picture it: Tigo fumbles their projections, and boy does it sting. They're caught in the crossfire for allegedly puffing up their revenue expectations tied to a venture with EG4 Electronics—poised to churn out...

Continue Reading
Rising Food Safety Stars Honored: A Global Effort

Updated Category News Views 2

Food Safety Breakthrough: Youth Leads the Charge When it comes to food safety, it’s about time the younger crowd gets their due. The latest crew to step up to the plate is the Class of 2026's 40 Under 40 Food Safety Professionals. They’re not just pushing paper; these folks are setting the bar high and innovating across continents with real, tangible changes. From...

Continue Reading
Ellington's Q3 Earnings Call: What Investors Need to Know

Updated Category News Views 5

An Anticipated Unveiling Ellington Financial Inc. (NYSE:EFC) is gearing up to spill the beans on its third-quarter financials for 2026. It's all going down after the markets close on November 4th. I can tell you, folks, anyone keeping an eye on EFC will be itching to know what's inside those numbers. With a company this deep into financial assets, reading between the...

Continue Reading
Dott's Q3 2026: Micromobility Growth Soars High

Updated Category News Views 5

Riding the Wave of Profit in Micromobility Sometimes all you need is a quick jolt of genius to turn the wheels of fortune. Dott seems to have hit that sweet spot in Q3 of 2026. Deploying 45,000 new vehicles wasn’t just a logistical feat; it was a calculated bet that paid off handsomely, bolstering their business to soaring heights. Performance that Packs a Punch The Q3...

Continue Reading

Top 5 Most Recently Viewed Articles

ComFree's Remarkable Comeback: A New Era in Real Estate

Updated Category News Views 375

ComFree's Return to the Market After a notable absence, ComFree is back, igniting excitement in the real estate industry. The company's founders, Erin and Travis Holowach, originally created ComFree as a platform for homeowners to sell properties without agent interference, saving them significant fees. Their mission is now revitalized as they reclaim the brand they built...

Continue Reading
Why Capital Gains Tax Planning Matters for Long-Term Investors

Updated Category Investing Views 159

The average federal income tax paid by a typical person ranges from 13.5% to 15%, and tax planning is a mathematical necessity for anyone serious about building long-term wealth in the United States. Every dollar lost to an inefficient exit from an investment is a dollar that stops compounding for your future self. There are thousands of taxable events triggered daily...

Continue Reading
Biomea Fusion Reports Milestone 52-Week Findings in Diabetes

Updated Category News Views 164

Biomea Fusion Unveils Promising Efficacy of Icovamenib Biomea Fusion, Inc. (Nasdaq: BMEA), a pioneer in clinical-stage advancements for diabetes and obesity, recently announced significant 52-week results from its Phase II COVALENT-111 study. This study examined the potential effects of icovamenib, a novel treatment for type 2 diabetes (T2D), and the results underscore a...

Continue Reading
D-Wave Hit with Legal Scrutiny After Disappointing Q2

Updated Category News Views 23

D-Wave Quantum Under Legal Microscope Alright, folks, let's dive headfirst into some dicey financial waters with D-Wave Quantum Inc. (NASDAQ: QBTS). This quantum computing company is finding itself in a bit of a pickle following some rough second-quarter results that left investors scratching their heads. If you bought into the hype and are feeling the sting in your...

Continue Reading
Groundbreaking Debut of DeriW Exchange at Exclusive Event

Updated Category News Views 309

Groundbreaking Launch of DeriW Exchange DeriW, an innovative decentralized perpetual exchange, has officially launched during an exclusive event, showcasing its advanced features and capabilities. The event, hosted by CoinW, attracted 400 influential figures from the cryptocurrency sector. Among the attendees were thought leaders, blockchain pioneers, and affiliates, all...

Continue Reading